



Societal impact of the Novo Nordisk Foundation

Key facts and figures for 2020

“Investing in research and development in society contributes to creating knowledge, employment, growth and innovation of products and services to benefit people.”

— Lars Rebien Sørensen
Chairman, Board of Directors,
Novo Nordisk Foundation

Novo Nordisk Foundation

The Novo Nordisk Foundation is an independent Danish foundation with corporate interests which supports scientific, social and humanitarian causes. The Foundation's ambition is to strengthen research in Denmark and the Nordic countries while contributing to international collaboration, knowledge creation and growth to pave the way for societal development and solutions that improve the lives of people and create a sustainable society.


Our 2019–2023 strategy lays out the scope of our activities and how we will support projects in a wide range of fields, such as biomedical science, natural science, biotechnology, humanities, interdisciplinary research, diabetes treatment, innovation, education, outreach as well as social and humanitarian causes

The commercial activities are investments in life science companies, capital investments and controlling interest in Novo Nordisk A/S, Novozymes A/S and Novo Holdings A/S. With respect to the commercial activities, and if not otherwise stated the report focuses on the Novo Group and life science companies with equity investments where Novo Holdings' ownership share ranges between 5% and 100%.

This brochure presents some key facts and figures from the annual impact report showing the Foundation's input of resources and the subsequent effects on research, health and companies.

Mads Krogsgaard Thomsen
CEO
Novo Nordisk Foundation

Our nine principles for societal impact



The monetary
contribution to society

The societal impact of
grant-giving activities

The foundation's
commercial activities

This brochure is divided into our monetary contribution to society,
the societal impact of grant-giving activities and our commercial activities

5



Developing
innovative products
and solutions

6



Creating
jobs and growth

7



Developing
healthcare and
new medicine

8



Developing
world-class
education


9




Empowering
vulnerable groups
in society

Outcome, impact and long-term impact

Our business model 2020



Grant-giving
decision in 2020




DKK 8 billion
in dividends to the
Novo Nordisk Foundation

Societal impact

Novo Nordisk Foundation

The grant-giving finances

in the Novo Nordisk Foundation, 2016–2020




Novo Nordisk Foundation Group¹ finances

11% of public research and 18% of private research in Denmark



Public sector in Denmark




of research and development
expenditure in the
public sector financed by

Novo Nordisk Foundation

(DKK 2.9 billion in 2020)

Private sector in Denmark



of research and development
expenditure in the
private sector comes from the

Novo Nordisk Foundation Group

(DKK 7.5 billion in 2019)


¹ Novo Nordisk Foundation Group consists of the Novo Nordisk Foundation, the Novo Group as well as Novo Holdings A/S' life science and capital investments. The Novo Group comprises the Novo Nordisk A/S, Novozymes A/S and Novo Holdings A/S. Novo Holdings A/S is fully owned by the Foundation.

22% increase in people

fully or partly supported by the Foundation in 2020

People supported by grants

People outside
science




People in
science



People supported in science


♂
52%
Male



♀
48%
Female

2,200 PhD students & postdoctoral fellows are fully or partly supported by the Foundation in 2020

Medical and health sciences




of Danish PhD students
within medical and health sciences
are fully or partly funded by

Novo Nordisk Foundation grants



Natural sciences





of Danish PhD students
within natural sciences
are fully or partly funded by

Novo Nordisk Foundation grants




Since 2016, our grant recipients have published more than 10,000 journal articles

and 23% of Foundation-funded articles are among
world's top 10% most cited (2016–2019)




Number of journal articles per million population in selected countries, 2020

and the Foundation-funded share of journal articles in the Nordic countries



The Novo Nordisk Foundation Group

contributed to translation of research to medicines through 334 clinical trials in 2020




More than 26,000 patients were treated

at the Steno Diabetes Centres in 2020



Type 1 diabetes
patients

14,300



Type 2 diabetes
patients

10,800




Other
patients

1,100




Foundation-funded journal articles

contribute to the treatment of patients within
the four Non-Communicable Diseases



21%

of 870 national and international
clinical guidelines and treatment
recommendations cite Foundation-
funded research (2011-2020)




References in national and international clinical guidelines

and treatment recommendations within NCDs

Diabetes




122 guidelines



Cardiology




241 guidelines



Cancer




355 guidelines



Respiratory diseases





152 guidelines



of the guidelines are citing Foundation funded research

18% of Foundation funded research is cited in patents






Public research spillover through industry collaboration and patent activities




Number of people using the products

from the Novo Group and Novo Holdings' life science portfolio in 2020

Users of MedTech products



Users of medicine




The companies in the Novo Nordisk Foundation Group

account for 14% of Danish published patents
and 20% of Danish granted patents




Share of Danish
patent applications



1,699 patent applications
worldwide in 2020

Share of Danish
granted patents



595 patents
worldwide in 2020





Benefiting people and society

Novo Nordisk Foundation
Tuborg Havnevej 19
DK-2900 Hellerup
Denmark

T +45 3527 6600
E nnfond@novo.dk
W novonordiskfoundation.com